Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

A new device is transforming the type of treatment some heart patients with atrial fibrillation receive. Doctors say it’s ...

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

填写文字，插入到文章（开头、中间、末尾）！ 2025年2月5日，波士顿科学公布了2024年第四季度及全年业绩。其中，电生理业务第四季度销售额为6.49亿美元，全年销售额为19亿美元，分别同比增长近171%和138%。 财报称，在2024年初获得 FDA 批准后，其 FARAPULSE脉冲场消融系统到2024年底的销售额超过10亿美元（72.88亿美元）。 该公司领导层此前曾将 FARAPULSE描 ...

The company states: “Boston Scientific (BSX) announced data supporting the use of the FARAPULSE Pulsed Field Ablation System* and the WATCHMAN FLX Left Atrial Appendage Closure Device ...

当前，中国植介入及心血管市场正以前所未有的速度蓬勃发展，创新技术如雨后春笋般竞相涌现，展现出百花齐放的繁荣景象。2024年，器械之家及旗下媒体矩阵发布了近千篇深度聚焦该领域的报道，生动描绘了这一行业的蓬勃热度和无限活力。

In late-breaking data presentations, the ADVANTAGE AF trial for the Farapulse PFA system met its primary endpoints, showing a 2.3% safety event rate and 63.5% effectiveness rate in treating persistent ...

Boston Scientific Corporation BSX recently presented data supporting the use of the FARAPULSE Pulsed Field Ablation (“PFA”) system and the WATCHMAN Left Atrial Appendage Closure (“LAAC ...

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

从临床突破到耗材革命，电生理人如何共享红利？ 当手术成功率撞上耗材成本——一场电生理人的集体突围 ...

Boston Scientific reported that electrophysiology sales grew 172% in Q4 2024, driven by an uptake of its Farapulse pulsed field ablation (PFA) system. Revealing its Q4 and full-year results ...